Inion Oyj - Company Announcement

New Inion spinal implant system expands portfolio to cover applications across the entire spine

New Inion spinal implant system expands portfolio to cover applications across 
                                the entire spine                                

   Inion S-2™ biodegradable spinal fusion system receives European regulatory   
                                   clearance                                    


Tampere, Finland and Guildford, UK. 17 October 2007…Inion [LSE: IIN.L], a       
company focused on the development of novel biodegradable medical implants, has 
received CE Mark* from the British Standards Institution (BSI) for its new Inion
S-2™ Anterior Lumbar Fusion System.                                             

The new Inion S-2™ system is intended for use as a graft containment device in  
spinal fusion procedures in the lumbar regions of the spine (lower back) in     
combination with rigid fixation. It can also be used in thoracic regions        
(mid-to-upper back) meaning that, in addition to the Inion S-1™ system (for     
applications in the cervical or neck region), Inion now has biodegradable       
implants for application over the whole spine.                                  

Furthermore, the new system also incorporates Inion's new radiographic tracer   
technology, which allows proper post-operative evaluation of healing at the     
operated sites. The technology involves the incorporation of a radiographic     
marker at the edges of the plates and on the tips of screws in the form of      
dot-like markers, enabling surgeons to view the position of the implants in     
post-operative x-ray without interfering with their assessment of the site of   
surgery and its healing progress.                                               
                                                                                
Chris Lee, Inion's CEO, said: “This is an important new product approval for    
Inion and significantly enhances our portfolio of biodegradable implants for    
spinal applications. With full coverage of the spine for a range of surgical    
procedures we believe we have an attractive product offering that will help us  
build an increasing presence in the large and rapidly growing spinal implant    
market.”                                                                        

*CE Mark is issued by a number of accredited bodies to medical device           
manufacturers prior to commercial distribution in the European Union.           
		                                                                              
                                                             -Ends-             

For further information, please contact:                                        
--------------------------------------------------------------------------------
| Inion Oy                                   | Tel: +44 (0)1483 685390         |
| Chris Lee, Chief Executive                 |                                 |
| Officer                                    |                                 |
| Julien Cotta, Chief Financial              |                                 |
| Officer                                    |                                 |
--------------------------------------------------------------------------------
| Citigate Dewe Rogerson                     | Tel: +44 (0)207 638 9571        |
| Mark Swallow /                             |                                 |
| David Dible                                |                                 |
--------------------------------------------------------------------------------

About Inion (www.inion.com)                                                     
Inion Oy is a medical devices company focused on the development and successful 
commercialisation of innovative biodegradable and bioactive implants in key     
target markets. The Company's target segments are Spine and Specialty           
Orthopaedics.                                                                   

Inion's core expertise and technology lies in the design and manufacture of     
innovative biodegradable plates, screws, pins and membranes, which are used to  
enhance the healing of bone or soft tissue injuries to the skeleton, such as    
those caused by trauma or by reconstructive surgery. Inion implants are made    
from its proprietary Inion Optima™ family of biomaterials, with properties      
tailored for specific surgical applications, in terms of strength, flexibility  
and rate of degradation                                                         
                                                                                
Inion is also focused on developing proprietary new bioactive and               
biodegradable biomaterials that promote bone healing and accelerate patient     
rehabilitation.                                                                 

Inion was incorporated in early 2000 and listed on the Official List of the UK  
Listing Authority in December 2004. The Company has an office and an R&D        
facility in the UK and head office, R&D and production facilities in Tampere,   
Finland.                                                                        

This announcement includes "forward-looking statements" which include all       
statements other than statements of historical facts, including, without        
limitation, those regarding the Group's financial position, business strategy,  
plans and objectives of management for future operations (including development 
plans and objectives relating to the Group's products), and any statements      
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will", 
"can", "may", "anticipates", "would", "should", "could" or similar expressions  
or the negative thereof. Such forward-looking statements involve known and      
unknown risks, uncertainties and other important factors beyond the Group's     
control that could cause the actual results, performance or achievements of the 
Group to be materially different from future results, performance or            
achievements expressed or implied by such forward-looking statements. Such      
forward-looking statements are based on numerous assumptions regarding the      
Group's present and future business strategies and the environment in which the 
Group will operate in the future. Among the important factors that could cause  
the Group's actual results, performance or achievements to differ materially    
from those in forward-looking statements include those relating to Inion's      
funding requirements, regulatory approvals, reliance on third parties,          
intellectual property, key personnel and other factors. These forward-looking   
statements speak only as at the date of this announcement. The Group expressly  
disclaims any obligation or undertaking to disseminate any updates or revisions 
to any forward-looking statements contained in this announcement to reflect any 
change in the Group's expectations with regard thereto or any change in events, 
conditions or circumstances on which any such statements are based. As a result 
of these factors, prospective investors are cautioned not to rely on any        
forward-looking statement.